Johnson & Johnson Unveils Details On Ottava Soft-Tissue Robot, Chasing Intuitive, Medtronic

J&J said its Ottava robotic platform has six robotic arms, “zero footprint,” and can be used for various procedures.

Robots in medicine. Innovative medicine. Robotic surgery.

Johnson & Johnson (Pty) Ltd released details of its much-anticipated Ottava robotic surgery platform for soft-tissue procedures during the company’s virtual medical device update on 19 November.

The platform is slated to enter human clinical trials in the second half of 2022 with a possible launch expected in 2023 or 2024, which will likely put it third to market behind market leader Intuitive Surgical, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Robotic Surgery

More from Surgery

Medtronic Presents Data To Boost Hugo’s Odds Of Getting FDA Nod

 

Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.

HRS Released Framework For Afib Center Of Excellence To Improve Outcomes Through Multidisciplinary Care

 
• By 

Medtech Insight sat down with Jared Bunch, chair of AF Center of Excellence Task Force, at HRS 2025 to discuss the newly HRS released framework for Afib Center of Excellence and get his perspective on the role industry could play to help clinicians improve patient outcomes.

Q’Apel Medical Recalls, Discontinues Stroke Therapy System After FDA Warning Letter, Class I Designation

 

Q’Apel Medical has pulled its aspiration system for stroke thrombectomy from the market after concerns raised by the US FDA in a February warning letter.